LIVIVO - Search results -

Search results

Result 1 - 10 of total 67

Search options

Article ; Online: Rendezvous therapy with endoscopic and endovascular treatments for rectal arteriovenous malformation: A case report.

Matsuda, Takashi / Ishikawa, Tsuyoshi / Oono, Takashi / Sasaki, Ryo / Hidaka, Isao / Okada, Munemasa / Sakaida, Isao

2021 Volume 54, Issue 3, Page(s) E77–E78

MeSH term(s)	Arteriovenous Malformations/diagnostic imaging ; Arteriovenous Malformations/surgery ; Embolization, Therapeutic ; Endoscopy ; Humans
Language	English
Publishing date	2021-03-15
Publishing country	Germany
Document type	Case Reports ; Journal Article
ZDB-ID	80120-3
ISSN	1438-8812 ; 0013-726X
ISSN (online)	1438-8812
ISSN	0013-726X
DOI	10.1055/a-1388-6021
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 669: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 162: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Rendezvous therapy with endoscopic and endovascular treatments for rectal arteriovenous malformation: A case report

Matsuda, Takashi / Ishikawa, Tsuyoshi / Oono, Takashi / Sasaki, Ryo / Hidaka, Isao / Okada, Munemasa / Sakaida, Isao

Endoscopy

2021 Volume 54, Issue 03, Page(s) E77–E78

Language	English
Publishing date	2021-03-15
Publisher	Georg Thieme Verlag KG
Publishing place	Stuttgart ; New York
Document type	Article
ZDB-ID	80120-3
ISSN	1438-8812 ; 0013-726X
ISSN (online)	1438-8812
ISSN	0013-726X
DOI	10.1055/a-1388-6021
Database	Thieme publisher's database

In stock of ZB MED Cologne/Königswinter

Zs.A 669: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 162: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Unique skin manifestations of COVID-19: Is drug eruption specific to COVID-19?

Sakaida, Takashi / Tanimoto, Isao / Matsubara, Akihiro / Nakamura, Motoki / Morita, Akimichi

Journal of dermatological science

2020 Volume 99, Issue 1, Page(s) 62–64

MeSH term(s)	Anti-Inflammatory Agents, Non-Steroidal/adverse effects ; Betacoronavirus ; COVID-19 ; Cephalosporins/adverse effects ; Coronavirus Infections/complications ; Drug Eruptions/virology ; Female ; Humans ; Middle Aged ; Pandemics ; Phenylpropionates/adverse effects ; Pneumonia, Viral/complications ; SARS-CoV-2
Chemical Substances	Anti-Inflammatory Agents, Non-Steroidal ; Cephalosporins ; Phenylpropionates ; loxoprofen (3583H0GZAP) ; cefcapene pivoxil hydrochloride (5J77167P9E)
Keywords	covid19
Language	English
Publishing date	2020-05-16
Publishing country	Netherlands
Document type	Case Reports ; Letter
ZDB-ID	1024446-3
ISSN	1873-569X ; 0923-1811
ISSN (online)	1873-569X
ISSN	0923-1811
DOI	10.1016/j.jdermsci.2020.05.002
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2870: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Differential clinical impact of letermovir prophylaxis according to graft sources: a KSGCT multicenter retrospective analysis.

Blood advances

2024 Volume 8, Issue 5, Page(s) 1084–1093

Abstract: Abstract: Clinically significant cytomegalovirus infection (csCMVi) is frequently observed after allogeneic hematopoietic stem cell transplantation (HSCT) and prophylaxis with letermovir is commonly adopted. However, the clinical benefit of letermovir ... ...

Abstract	Abstract: Clinically significant cytomegalovirus infection (csCMVi) is frequently observed after allogeneic hematopoietic stem cell transplantation (HSCT) and prophylaxis with letermovir is commonly adopted. However, the clinical benefit of letermovir prophylaxis according to graft sources has not been sufficiently elucidated. We retrospectively analyzed 2194 recipients of HSCT who were CMV-seropositive (236 with letermovir prophylaxis and 1958 without prophylaxis against CMV). csCMVi was significantly less frequent in patients with letermovir prophylaxis than in those without (23.7% vs 58.7% at 100 days after HSCT, P < .001) and the same trend was seen when recipients of bone marrow (BM), peripheral blood stem cell (PBSC), or cord blood (CB) transplantation were separately analyzed. In recipients of BM, nonrelapse mortality (NRM) was significantly lower in the letermovir group at 6 months after HSCT (5.0% vs 14.9%, P = .018), and the same trend was observed in recipients of PBSCs (14.7% vs 24.8%, P = .062); however, there was no statistical significance at 1 year (BM, 21.1% vs 30.4%, P = .67; PBSCs, 21.2% vs 30.4%, P = .096). In contrast, NRM was comparable between recipients of CB with and without letermovir prophylaxis throughout the clinical course (6 months, 23.6% vs 24.3%, P =.92; 1 year, 29.3% vs 31.0%, P = .77), which was confirmed by multivariate analyses. In conclusion, the impact of letermovir prophylaxis on NRM and csCMVi should be separately considered according to graft sources.
MeSH term(s)	Humans ; Retrospective Studies ; Antiviral Agents/therapeutic use ; Hematopoietic Stem Cell Transplantation/adverse effects ; Cytomegalovirus Infections/prevention & control ; Acetates ; Quinazolines
Chemical Substances	letermovir (1H09Y5WO1F) ; Antiviral Agents ; Acetates ; Quinazolines
Language	English
Publishing date	2024-02-08
Publishing country	United States
Document type	Multicenter Study ; Journal Article
ZDB-ID	2915908-8
ISSN	2473-9537 ; 2473-9529
ISSN (online)	2473-9537
ISSN	2473-9529
DOI	10.1182/bloodadvances.2023010735
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7153: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Unique skin manifestations of COVID-19: Is drug eruption specific to COVID-19?

Sakaida, Takashi / Tanimoto, Isao / Matsubara, Akihiro / Nakamura, Motoki / Morita, Akimichi

J Dermatol Sci

Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #276300
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Unique skin manifestations of COVID-19

Sakaida, Takashi / Tanimoto, Isao / Matsubara, Akihiro / Nakamura, Motoki / Morita, Akimichi

Journal of Dermatological Science

Is drug eruption specific to COVID-19?

2020 Volume 99, Issue 1, Page(s) 62–64

Keywords	Biochemistry ; Molecular Biology ; Dermatology ; covid19
Language	English
Publisher	Elsevier BV
Publishing country	us
Document type	Article ; Online
ZDB-ID	1024446-3
ISSN	0923-1811
ISSN	0923-1811
DOI	10.1016/j.jdermsci.2020.05.002
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

In stock of ZB MED Cologne/Königswinter

Zs.A 2870: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Bone marrow-derived humoral factors suppress oxidative phosphorylation, upregulate TSG-6, and improve therapeutic effects on liver injury of mesenchymal stem cells.

Miyaji, Takashi / Takami, Taro / Fujisawa, Koichi / Matsumoto, Toshihiko / Yamamoto, Naoki / Sakaida, Isao

Journal of clinical biochemistry and nutrition

2020 Volume 66, Issue 3, Page(s) 213–223

Abstract: Mesenchymal stem cells, which have the potential to be used in regenerative medicine, require improvements in quality for patient use. To maintain stemness of cultured bone marrow-derived mesenchymal stem cells, we focused on the bone marrow ... ...

Abstract	Mesenchymal stem cells, which have the potential to be used in regenerative medicine, require improvements in quality for patient use. To maintain stemness of cultured bone marrow-derived mesenchymal stem cells, we focused on the bone marrow microenvironment, generated a conditioned medium of whole bone marrow cells (BMC-CM), and assessed its effects on bone marrow-derived mesenchymal stem cells. BMC-CM suppressed morphological deterioration and proliferative decline in cultured bone marrow-derived mesenchymal stem cells, suppressed mitochondrial oxidative phosphorylation activity, a stemness indicator, and upregulated suppressors of oxidative phosphorylation such as hypoxia-inducible factor-1 alpha, Sirtuin 3, 4, and 5. Furthermore, BMC-CM upregulated TNF-stimulated gene 6 and ameliorated the therapeutic effects of cells on liver injury in carbon tetrachloride-administered rats. Since the elimination of 20-220-nm particles attenuated the effects of BMC-CM, we further analyzed exosomal microRNAs produced by whole bone marrow cells. Among the 49 microRNAs observed to be upregulated during the preparation of BMC-CM, several were identified that were associated with suppression of oxidative phosphorylation, upregulation of TNF-stimulated gene 6, and the pathogenesis of liver diseases. Thus, bone marrow-derived humoral factors including exosomal microRNAs may help to improve the therapeutic quality of bone marrow-derived mesenchymal stem cells for liver regenerative therapy.
Language	English
Publishing date	2020-03-06
Publishing country	Japan
Document type	Journal Article
ZDB-ID	632945-7
ISSN	1880-5086 ; 0912-0009
ISSN (online)	1880-5086
ISSN	0912-0009
DOI	10.3164/jcbn.19-125
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2981: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Successful Management With Dual Therapy of Lenvatinib and Macitentan for HCC With Portopulmonary Hypertension.

Ishikawa, Tsuyoshi / Sasaki, Ryo / Matsuda, Takashi / Saeki, Issei / Takami, Taro / Wada, Yasuaki / Yano, Masafumi / Sakaida, Isao

Hepatology (Baltimore, Md.)

2021 Volume 74, Issue 4, Page(s) 2300–2303

MeSH term(s)	Aged ; Carcinoma, Hepatocellular/drug therapy ; Carcinoma, Hepatocellular/etiology ; Carcinoma, Hepatocellular/pathology ; Cardiac Catheterization/methods ; Endothelin Receptor Antagonists/administration & dosage ; Hepatitis B, Chronic/complications ; Humans ; Hypertension, Portal/diagnosis ; Hypertension, Portal/etiology ; Hypertension, Portal/physiopathology ; Liver Cirrhosis/etiology ; Liver Cirrhosis/pathology ; Liver Neoplasms/drug therapy ; Liver Neoplasms/etiology ; Liver Neoplasms/pathology ; Male ; Medication Therapy Management ; Phenylurea Compounds/administration & dosage ; Phenylurea Compounds/adverse effects ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Protein-Tyrosine Kinases/antagonists & inhibitors ; Pulmonary Arterial Hypertension/diagnosis ; Pulmonary Arterial Hypertension/etiology ; Pulmonary Arterial Hypertension/physiopathology ; Pulmonary Arterial Hypertension/therapy ; Pyrimidines/administration & dosage ; Quinolines/administration & dosage ; Quinolines/adverse effects ; Sulfonamides/administration & dosage ; Tomography, X-Ray Computed/methods ; Treatment Outcome
Chemical Substances	Endothelin Receptor Antagonists ; Phenylurea Compounds ; Protein Kinase Inhibitors ; Pyrimidines ; Quinolines ; Sulfonamides ; Protein-Tyrosine Kinases (EC 2.7.10.1) ; lenvatinib (EE083865G2) ; macitentan (Z9K9Y9WMVL)
Language	English
Publishing date	2021-06-18
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	604603-4
ISSN	1527-3350 ; 0270-9139
ISSN (online)	1527-3350
ISSN	0270-9139
DOI	10.1002/hep.31865
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1660: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Splenic non-infarction volume determines a clinically significant hepatic venous pressure gradient response to partial splenic embolization in patients with cirrhosis and hypersplenism.

Ishikawa, Tsuyoshi / Sasaki, Ryo / Nishimura, Tatsuro / Matsuda, Takashi / Iwamoto, Takuya / Saeki, Issei / Hidaka, Isao / Takami, Taro / Sakaida, Isao

Journal of gastroenterology

2021 Volume 56, Issue 4, Page(s) 382–394

Abstract: Background: This study aimed to investigate changes in the hepatic venous pressure gradient (HVPG) by partial splenic embolization (PSE) and to identify the determinants of a clinically meaningful postoperative HVPG reduction.: Methods: Sixty-eight ... ...

Abstract	Background: This study aimed to investigate changes in the hepatic venous pressure gradient (HVPG) by partial splenic embolization (PSE) and to identify the determinants of a clinically meaningful postoperative HVPG reduction. Methods: Sixty-eight patients with cirrhosis and hypersplenism who underwent PSE at our department between September 2007 and June 2020 were included. The HVPG was evaluated pre- and immediately post-PSE. The patients were divided into three groups according to their preprocedural HVPG: low-HVPG (< 10 mmHg, n = 22), intermediate-HVPG (10 mmHg ≤ HVPG < 16 mmHg, n = 33), and high-HVPG (≥ 16 mmHg, n = 13). Results: Overall, PSE significantly reduced HVPG from 12.2 ± 4.0 to 9.4 ± 3.6 mmHg (p < 0.01) with a relative decrease of 22.2 ± 20.4%. In addition, HVPG reductions were 19.4 ± 28.7%, 24.0 ± 15.9%, and 22.5 ± 13.3% in the low-, intermediate-, and high-HVPG groups, respectively, indicating no significant difference in HVPG reduction between the groups. An HVPG decrease of ≥ 20% from the baseline, defined in this study as a clinically significant HVPG response to PSE, was achieved in 55.9% of all patients. Multivariate logistic regression and receiver operating characteristic curve analyses identified splenic non-infarction volume as an independent determinant of a 20% decrease in HVPG (p < 0.05), with a cut-off of 139.2 cm Conclusions: The splenic non-infarction volume, namely the residual functional spleen volume, independently determines a clinically significant HVPG response to PSE in patients with cirrhosis and hypersplenism.
MeSH term(s)	Adult ; Embolization, Therapeutic/methods ; Embolization, Therapeutic/standards ; Embolization, Therapeutic/statistics & numerical data ; Female ; Fibrosis/drug therapy ; Fibrosis/physiopathology ; Humans ; Hypersplenism/drug therapy ; Hypersplenism/physiopathology ; Liver/physiology ; Liver/physiopathology ; Male ; Middle Aged ; Portal Pressure/physiology ; Spleen/injuries ; Spleen/physiopathology ; Statistics, Nonparametric ; Venous Pressure/physiology
Language	English
Publishing date	2021-02-24
Publishing country	Japan
Document type	Journal Article
ZDB-ID	1186495-3
ISSN	1435-5922 ; 0944-1174
ISSN (online)	1435-5922
ISSN	0944-1174
DOI	10.1007/s00535-021-01762-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 620: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A.

Shima, Midori / Amano, Kagehiro / Ogawa, Yoshiyuki / Yoneyama, Koichiro / Ozaki, Ryoto / Kobayashi, Ryota / Sakaida, Emiko / Saito, Makoto / Okamura, Takashi / Ito, Toshihiro / Hattori, Norimichi / Higasa, Satoshi / Suzuki, Nobuaki / Seki, Yoshinobu / Nogami, Keiji

Journal of thrombosis and haemostasis : JTH

2022 Volume 21, Issue 3, Page(s) 534–545

Abstract: Background: Emicizumab is a bispecific antibody that mimics the cofactor function of activated factor (F) VIII. It prevents bleeds in patients with congenital hemophilia A regardless of the inhibitor status; however, no prospective clinical studies have ...

Abstract	Background: Emicizumab is a bispecific antibody that mimics the cofactor function of activated factor (F) VIII. It prevents bleeds in patients with congenital hemophilia A regardless of the inhibitor status; however, no prospective clinical studies have been conducted for emicizumab in patients with acquired hemophilia A (PwAHA). Objectives: To describe the primary analysis results from a prospective, multicenter, open-label phase III study evaluating the efficacy, safety, and pharmacokinetics of emicizumab in PwAHA (AGEHA; JapicCTI-205151). Methods: Emicizumab was administered subcutaneously at 6 mg/kg on day 1 and 3 mg/kg on day 2, followed by 1.5 mg/kg once weekly from day 8 onward. Predefined criteria for the completion of dosing included FVIII activity of >50 IU/dL. Results: By the cutoff date (April 23, 2021), 12 patients on immunosuppressive therapy were enrolled, and 11 of them (91.7%) completed emicizumab treatment. The mean trough plasma emicizumab concentration rapidly reached a steady state (1 week), achieving the efficacious level that was established in patients with congenital hemophilia A (>30 μg/mL). Before first emicizumab administration, 7 patients (58.3%) experienced 77 major bleeds. During emicizumab treatment, no major bleeds occurred in any patient. Neither death due to bleeding or infection nor any study treatment-related serious adverse event was reported. One asymptomatic, nonserious deep vein thrombosis was discovered with no laboratory findings indicating any trend toward hypercoagulation. Conclusion: These results suggest that emicizumab prophylaxis with the tested dosing regimen and completion criteria may have a favorable benefit-risk profile in PwAHA.
MeSH term(s)	Humans ; Hemophilia A/drug therapy ; Factor VIII ; Hemorrhage/chemically induced ; Antibodies, Bispecific/therapeutic use
Chemical Substances	Factor VIII (9001-27-8) ; emicizumab (7NL2E3F6K3) ; Antibodies, Bispecific
Language	English
Publishing date	2022-12-22
Publishing country	England
Document type	Clinical Trial, Phase III ; Multicenter Study ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2112661-6
ISSN	1538-7836 ; 1538-7933
ISSN (online)	1538-7836
ISSN	1538-7933
DOI	10.1016/j.jtha.2022.10.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5805: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 295: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito